CN110461329A - 治疗血癌的PPARγ激动剂 - Google Patents

治疗血癌的PPARγ激动剂 Download PDF

Info

Publication number
CN110461329A
CN110461329A CN201780063382.4A CN201780063382A CN110461329A CN 110461329 A CN110461329 A CN 110461329A CN 201780063382 A CN201780063382 A CN 201780063382A CN 110461329 A CN110461329 A CN 110461329A
Authority
CN
China
Prior art keywords
leukemia
therapeutically effective
effective amount
myeloma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780063382.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·曼特佐罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellin Therapeutic Co Ltd
Original Assignee
Intellin Therapeutic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellin Therapeutic Co Ltd filed Critical Intellin Therapeutic Co Ltd
Publication of CN110461329A publication Critical patent/CN110461329A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201780063382.4A 2016-08-18 2017-08-18 治疗血癌的PPARγ激动剂 Pending CN110461329A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376749P 2016-08-18 2016-08-18
US62/376,749 2016-08-18
PCT/US2017/047578 WO2018035446A1 (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Publications (1)

Publication Number Publication Date
CN110461329A true CN110461329A (zh) 2019-11-15

Family

ID=61197183

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780063382.4A Pending CN110461329A (zh) 2016-08-18 2017-08-18 治疗血癌的PPARγ激动剂

Country Status (12)

Country Link
US (1) US20210379049A1 (enExample)
EP (1) EP3500268A4 (enExample)
JP (2) JP2019524888A (enExample)
KR (1) KR20190064573A (enExample)
CN (1) CN110461329A (enExample)
AU (1) AU2017313839A1 (enExample)
BR (1) BR112019003130A2 (enExample)
CA (1) CA3034258A1 (enExample)
EA (1) EA201990512A1 (enExample)
MX (1) MX2019001979A (enExample)
SG (2) SG10202101501PA (enExample)
WO (1) WO2018035446A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
WO2020243058A1 (en) * 2019-05-30 2020-12-03 Coherus Biosciences, Inc. Compositions and methods to treat cancer
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228622A (zh) * 2013-01-30 2016-01-06 因特克林医疗有限公司 用于治疗多发性硬化的PPARγ激动剂
CN109414506A (zh) * 2016-06-08 2019-03-01 投资支持有限公司 用于治疗癌症的药物组合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018186B1 (ja) * 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228622A (zh) * 2013-01-30 2016-01-06 因特克林医疗有限公司 用于治疗多发性硬化的PPARγ激动剂
CN109414506A (zh) * 2016-06-08 2019-03-01 投资支持有限公司 用于治疗癌症的药物组合

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AVCLL FERIT 等: "Association of Plasma Adiponectin Concentrations with Chronic Lymphocytic Leukemia and Myeloproliferative Diseases", 《INTERNATIONAL JOURNAL OF HEMATOLOGY》 *
DANIEL NOWAK 等: "Differentiation therapy of leukemia: 3 decades of development", 《 BLOOD 》 *
DENISE M. RAY 等: "Human multiple myeloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands", 《CLINICAL IMMUNOLOGY》 *
LINDA S. HIGGINS 等: "The Development of INT131 as a Selective PPAR Modulator: Approach to a Safer Insulin Sensitizer", 《PPAR RESEARCH》 *
MD. MURAD HOSSAIN 等: "The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin", 《LIFE SCIENCES》 *

Also Published As

Publication number Publication date
CA3034258A1 (en) 2018-02-22
SG11201901320WA (en) 2019-03-28
WO2018035446A1 (en) 2018-02-22
KR20190064573A (ko) 2019-06-10
MX2019001979A (es) 2019-09-19
AU2017313839A1 (en) 2019-03-07
BR112019003130A2 (pt) 2019-05-21
JP2019524888A (ja) 2019-09-05
EP3500268A1 (en) 2019-06-26
SG10202101501PA (en) 2021-03-30
EP3500268A4 (en) 2020-04-15
US20210379049A1 (en) 2021-12-09
EA201990512A1 (ru) 2019-08-30
JP2022116304A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
JP2022116304A (ja) 血液がんの治療のためのＰＰＡＲγアゴニスト
McCormack et al. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia
US20110166092A1 (en) Dosing methods for treating disease
TW202241440A (zh) 預防或治療抗腫瘤劑相關疾病或病症的方法
EP4393490A1 (en) Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma
JP2001520656A (ja) 抗腫瘍剤としてのホルボールエステル類
WO2019178023A1 (en) Methods of Treating or Preventing Acute Respiratory Distress Syndrome
JP2019524888A5 (enExample)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
BRPI0620242A2 (pt) combinação compreendendo a combretastatina e agentes anti-cancerìgenos
KR20210095652A (ko) 스테로이드에 대한 내성을 극복하기 위한 글루타르이미드 유도체
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
JP2020536929A (ja) Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
CN117018202A (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
TWI862092B (zh) 用於預防或治療神經退化性疾病的藥物組合及方法
US20240207281A1 (en) Methods of treating b-cell lymphoma using combination therapy
TWI843217B (zh) 一種藥物組合及其應用
WO2020004404A1 (ja) ＩＬ－１β阻害薬
Youssef et al. Kasr-Al-Ainy cutaneous lymphoma unit protocol for management of mycosis fungoides
JP2001512446A (ja) メラニンによるサイトカインの調整
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
WO2023178255A9 (en) Combinations comprising metap2 inhibitors for the treatment of cancer
OA20849A (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
JPH11209302A (ja) 抗掻痒剤
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191115

WD01 Invention patent application deemed withdrawn after publication